BTMD

bioteB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$1.80

Analysis reference price unavailable

Analysis 2026-09-25 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.05

Analysis reference price unavailable

Analysis 2026-09-25 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$0.65

Analysis reference price unavailable

Analysis 2026-09-25 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-25

AI commentary

Company-confirmed recall damage and lower guidance keep the tone negative. The September 24 anchor is $1.23, but the packet does not establish an attributable immediate post-earnings price reaction. Post-print analyst revisions, social coverage, options skew, short interest and employee sentiment are unavailable; zero-valued sentiment fields indicate unavailable data, not neutral readings. No distinct, dated long-horizon program, partnership or financing trigger was verified, so this remains a tentative monitoring view.

RankAlpha Sentiment Codex - 2026-09-25

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-08-05eventQ2 recall impact and 2026 outlook cutHigh impact

The August 5 earnings release attached to the 8-K reported Q2 revenue of $44.2 million, down 9.5% year over year, and adjusted EBITDA of $5.6 million versus $15.2 million a year earlier. Management lowered its 2026 outlook to revenue above $175 million and adjusted EBITDA above $25 million. This is a completed negative event, not a prospective trigger. [#8-K-2026-08-05] [#SEC-8K-2026-08-05]

2026-09-30eventQuarterly debt-covenant testHigh impact

The amended credit agreement requires quarterly leverage and fixed-charge coverage tests. Biote reported compliance at June 30, but weaker EBITDA increases the importance of subsequent tests; the filing identifies September 30 as the start of scheduled quarterly term-loan repayments. [#10-Q-2026-08-07] [#SEC-10Q-2026-08-07]

2026-12-31catalystSecond-half procedure and margin recoveryHigh impact

Management expects sequential procedure-revenue improvement in Q3 and Q4 as Asteria inventory normalizes, but still expects year-over-year procedure declines in both quarters. Lower replacement-supplier costs could help margins; the recovery remains unproven. December 31 denotes the end of the stated second-half window, not an announced release date. [#SEC-8K-2026-08-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-25 • Updated nightlySource: Internal modelMethodology